3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
12
Breast Neoplasms
7
Neoplasm Metastasis
5
Lymphoma
5
Multiple Myeloma
4
Leukemia
4
Hematologic Neoplasms
4
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Depression
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Motor Activity
2
Malignant Female Reproductive System Neoplasm
2
Glioblastoma
2
Fatigue
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Caregiver Burden
2
Anxiety Disorders
2
Advanced Malignant Solid Neoplasm
2
Thyroid Neoplasms
1
Stroke
1
Stress Disorders, Post-Traumatic
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Initiation and Maintenance Disorders
1
Signs and Symptoms
1
Interventions
pembrolizumab
14
Nivolumab
11
Ipilimumab
10
cabozantinib
6
Axitinib
6
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Palliative Care
×
1 year
×
Clear all
NCT03652298
2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2
Terminated
19 enrolled